Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Saroj Vadhan-Raj, MD, Naomi V Dahl, Pharm.D., Gloria Lau, MSc, Kristine Bernard, Zhu Li, PhD, Pallabi De, PhD, Lee F. Allen, MD, PhD, William Strauss, M.D., F.A.C.C.

Blood (2013) 122 (21): 2201.

https://doi.org/10.1182/blood.V122.21.2201.2201

Published: 2013

Journal Articles

Ferumoxytol Treatment Demonstrates Significant Improvements in Fatigue and Health-Related Quality of Life in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy

Saroj Vadhan Raj, Andrew Hsieh, William Strauss, M.D., F.A.C.C., Michael Stevenson, R.Ph., Ph.D., Kristine Bernard, Lee F. Allen, MD, PhD

Blood (2012) 120 (21): 478.

https://doi.org/10.1182/blood.V120.21.478.478

Published: 2012

Journal Articles

Efficacy of Total Dose Administration (TDI) of 1012 Mg of Ferumoxytol Over 15 Minutes for the Treatment of Iron Deficient Anemia

Michael Auerbach, MD, William Strauss, M.D., F.A.C.C., Sarah Auerbach, Stella Rineer, Huzefa Bahrain

Blood (2012) 120 (21): 3204.

https://doi.org/10.1182/blood.V120.21.3204.3204

Published: 2012

Journal Articles

Ferumoxytol Treatment Results in Robust Hemoglobin Increases in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy in a Phase III, Randomized, Placebo-Controlled Trial.

Saroj Vadhan Raj, Michael Cressman, David Ford, William Strauss, M.D., F.A.C.C., Gerri Poss, Kristine Bernard, Zhu Li, PhD, Lee F. Allen, MD, PhD

Blood (2012) 120 (21): 2098.

https://doi.org/10.1182/blood.V120.21.2098.2098

Published: 2012

Journal Articles

Potential New Treatment Option for Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy- Results of a Phase III, Randomized, Open-Label, Active-Controlled Trial of Ferumoxytol.

David Hetzel, Audrone Urboniene, Kristine Bernard, William Strauss, M.D., F.A.C.C., Michael Cressman, Zhu Li, PhD, Lee F. Allen, MD, PhD

Blood (2012) 120 (21): 2099.

https://doi.org/10.1182/blood.V120.21.2099.2099

Published: 2012

NARROW

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Ferumoxytol Treatment Demonstrates Significant Improvements in Fatigue and Health-Related Quality of Life in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy

Efficacy of Total Dose Administration (TDI) of 1012 Mg of Ferumoxytol Over 15 Minutes for the Treatment of Iron Deficient Anemia

Ferumoxytol Treatment Results in Robust Hemoglobin Increases in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy in a Phase III, Randomized, Placebo-Controlled Trial.

Potential New Treatment Option for Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy- Results of a Phase III, Randomized, Open-Label, Active-Controlled Trial of Ferumoxytol.

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Ferumoxytol Treatment Demonstrates Significant Improvements in Fatigue and Health-Related Quality of Life in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy

Efficacy of Total Dose Administration (TDI) of 1012 Mg of Ferumoxytol Over 15 Minutes for the Treatment of Iron Deficient Anemia

Ferumoxytol Treatment Results in Robust Hemoglobin Increases in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy in a Phase III, Randomized, Placebo-Controlled Trial.

Potential New Treatment Option for Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy- Results of a Phase III, Randomized, Open-Label, Active-Controlled Trial of Ferumoxytol.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only